Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of TQB3473 in adults with primary immune thrombocytopenia
CTR20251074Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3473 in immune thrombocytopenia (ITP), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: active.
02
Drugs
TQB3473
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20251074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251074.